key: cord-0333257-3jqqei73 authors: Seow, Jeffrey; Graham, Carl; Hallett, Sadie R.; Lechmere, Thomas; Maguire, Thomas J.A.; Huettner, Isabella; Cox, Daniel; Roberts, Rebekah; Waters, Anele; Ward, Christopher C.; Mant, Christine; Pitcher, Michael J.; Spencer, Jo; Fox, Julie; Malim, Michael H.; Doores, Katie J. title: ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants date: 2021-09-28 journal: bioRxiv DOI: 10.1101/2021.09.27.461862 sha: c309c156486c03a4dcbe29f08cf97d941546a713 doc_id: 333257 cord_uid: 3jqqei73 Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that despite a relatively low serum neutralization titre, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (B.1.1.7, P.1, B.1.351 and B.1.617.2) were obtained. The vaccine elicited neutralizing mAbs form 8 distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222 elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post infection. Spike reactive IgG+ B cells were still detectable 9-months post boost. These findings give molecular insights into AZD1222 elicited antibody response. The SARS-CoV-2 encoded Spike glycoprotein is the key target for neutralizing 37 antibodies (nAbs) generated in response to natural infection. The Spike trimer consists of two 38 subunits, S1, that is required for interaction with the ACE-2 receptor on target cells, and S2 39 that orchestrates membrane fusion. Many monoclonal antibodies (mAbs) have been isolated detected in VA14 at 4-months post vaccine booster, nAbs were isolated which displayed 80 potent cross-neutralizing activity against SARS-CoV-2 viral variants of concern (IC 50 values 81 as low as 0.003 µg/mL). The AZD1222 vaccine elicited NTD-and RBD-specific nAbs that bind 82 epitopes overlapping with nAbs generated following natural infection. Assessment at 9-months 83 post vaccine booster revealed the presence of Spike reactive IgG+ B cells despite 84 undetectable neutralization. These data suggest that although plasma neutralization may be 85 sub-optimal for protection from infection, memory B cells may be sufficient to provide rapid 86 recall responses to protect from serious illness/hospitalizations upon re-infection. Serum neutralizing activity following AZD1222 vaccination 90 5 Plasma and peripheral blood mononuclear cells (PBMC) were isolated from donor 91 VA14 (23 years, white male) at 4-months (timepoint 1, TP1) and 9-months (timepoint 2, TP2) 92 after receiving two doses of the AZD1222 vaccine at a 12-week interval ( Figure 1A) . VA14 93 reported no previous SARS-CoV-2 infection (based on regular PCR testing), did not have N-94 specific IgG in their plasma at the time of sampling, and was therefore presumed to be SARS- CoV-2 naïve. Presence of IgG to Spike was determined by ELISA ( Figure 1B) and a semi-96 quantitative ELISA measured 0.39 and 0.17 µg/mL of Spike IgG at TP1 and TP2, respectively. Plasma neutralizing activity was measured using an HIV-1 (human immunodeficiency 98 virus type-1)-based virus particles, pseudotyped with Spikes of SARS-CoV-2 variants of 99 concern, including AZD1222 matched Spike (Wuhan-1, WT), and VOCs B. As the SARS-CoV-2 mAb database only included amino acid sequences for some mAbs, Additionally, the ability of nAbs to inhibit the interaction between Spike and the ACE2 receptor 178 was determined by flow cytometry (Figure 4D ). Four RBD neutralizing antibody classes have been previously identified and Interestingly, two NTD-specific mAbs that had shown no neutralizing activity against WT 241 pseudotyped virus, neutralized both B.1.1.7 and P.1 (Figure 5C ). The differences in 242 neutralization of VOCs by NTD-specific nAbs were reflected in their binding to S1 of VOCs by 243 ELISA (Figure S3B ). The S-only reactive nAbs elicited by vaccination did not neutralize any of the SARS- CoV-2 variants ( Figure 5D ). In contrast, the infection elicited S-only nAb retained modest 246 neutralization against P.1 at concentrations up to 47.7 µg/mL. Overall, AZD1222 vaccine elicited nAbs showed greater resistance to Spike mutations 248 in variants of concern compared to infection elicited nAbs ( Figure 5E ). In summary, we show that AZD1222 vaccine administered at a 12-week interval can 306 elicit nAbs with potent cross-neutralizing activity against SARS-CoV-2 VOCs that target non- Recombinant S1 (residues 1-530) and NTD (residues 1-310) expression and purification was Peter Cherepanov for S1 proteins from VOCs, Leo James and Jakub Luptak for the N protein, concern. nAbs are separated by competition group (Groups 1-4) . C) Neutralization by NTD-584 specific nAbs isolated following AZD1222 vaccination or SARS-CoV-2 infection against main 585 variants of concern. nAbs are separated by competition group (Groups 5, 6 and 8). D) Neutralization by S-only specific nAbs isolated following AZD1222 vaccination or SARS-CoV-587 2 infection against main variants of concern. Fold enhancement or reduction in neutralization Immunogenicity of Ad26.COV2.S 596 vaccine against SARS-CoV-2 variants in humans SARS-CoV-2 mRNA vaccination induces 599 functionally diverse antibodies to NTD, RBD, and S2 Seasonal human coronavirus 602 antibodies are boosted upon SARS-CoV-2 infection but not associated with protection Hybrid immunity improves B cell frequency, antibody potency and breath 605 against SARS-CoV-2 and variants of concern Extremely potent human monoclonal 608 antibodies from COVID-19 convalescent patients A time-and cost-efficient system for high-level 610 protein production in mammalian cells Efficacy and Safety of the mRNA-1273 SARS CoV-2 Vaccine SARS-CoV-2 neutralizing 616 antibody structures inform therapeutic strategies An anti-SARS-CoV-2 non-neutralizing antibody with Fc-618 effector function defines a new NTD epitope and delays neuroinvasion and death in K18-619 hACE2 mice IMGT/V-QUEST: the highly customized 621 and integrated system for IG and TR standardized V-J and V-D-J sequence analysis Potent neutralizing 625 antibodies from COVID-19 patients define multiple targets of vulnerability Peripheral immunophenotypes in children with 629 multisystem inflammatory syndrome associated with SARS-CoV-2 infection Potent SARS-CoV-2 neutralizing antibodies directed against spike 632 N-terminal domain target a single supersite Anti-SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA 634 Vaccination. bioRxiv Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-637 elicited antibodies Tackling COVID-19 with neutralizing 639 monoclonal antibodies IgV somatic mutation of human anti-642 SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity The antigenic anatomy of SARS-CoV-2 646 receptor binding domain Mechanisms of immunoglobulin deactivation by Streptococcus pyogenes Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine 654 against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a 655 randomised controlled trial Evolution of antibody 658 immunity to SARS-CoV-2 Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of 662 Concern. bioRxiv Neutralization potency of monoclonal antibodies 665 recognizing dominant and subdominant epitopes on SARS-CoV-2 An optimised method for the production of 668 MERS-CoV spike expressing viral pseudotypes Complex heatmaps reveal patterns and correlations 670 in multidimensional genomic data Monovalent, reduced-size quantum dots for imaging 673 receptors on living cells An mRNA 676 Vaccine against SARS-CoV-2 -Preliminary Report Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein 679 receptor binding domain in patients with COVID-19 and healthy individuals In vitro and in vivo functions of SARS-CoV-2 683 infection-enhancing and neutralizing antibodies .617 by vaccine and convalescent serum Potent neutralizing antibodies against multiple epitopes on SARS-689 CoV-2 spike Effectiveness of Covid-19 Vaccines 692 against the B.1.617.2 (Delta) Variant Efficacy of the Covid-19 Vaccine against the B.1.351 Variant N-terminal domain antigenic mapping reveals a site 698 of vulnerability for SARS-CoV-2 immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with 702 cancer: interim analysis of a prospective observational study Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape 706 mutations Mapping Neutralizing and 709 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-710 Comparative assessment of multiple COVID-713 19 serological technologies supports continued evaluation of point-of-care lateral flow assays 714 in hospital and community healthcare settings Safety and Efficacy of the BNT162b2 717 mRNA Covid-19 Vaccine Safety and immunogenicity of 720 ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults 721 (COV002): a single-blind, randomised, controlled, phase 2/3 trial CoV-AbDab: the 723 coronavirus antibody database The effect of spike mutations on SARS-CoV-2 726 neutralization Convergent antibody responses to 729 SARS-CoV-2 in convalescent individuals Isolation of potent SARS-CoV-2 neutralizing antibodies and 732 protection from disease in a small animal model SARS-CoV-2 recruits a haem metabolite to evade 735 antibody immunity SARS-CoV-2 can recruit a haem metabolite 738 to evade antibody immunity Broad diversity of neutralizing antibodies 741 isolated from memory B cells in HIV-infected individuals Longitudinal observation and decline of 744 neutralizing antibody responses in the three months following SARS-CoV-2 infection in 745 humans Analysis of a SARS-CoV Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited 749 Two subsets of human marginal zone B cells resolved by global analysis 751 of lymphoid tissues and blood Reduced neutralization of 754 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Neutralizing and protective human 757 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Detection of neutralising 761 antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors 762 between Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR 765 and expression vector cloning Ultrapotent human antibodies protect 768 against SARS-CoV-2 challenge via multiple mechanisms Sequencing and cloning of antigen-specific antibodies from 771 mouse memory B cells Safety and efficacy of the ChAdOx1 774 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 775 controlled trials in Brazil, South Africa, and the UK AZD1222-induced neutralising antibody activity 778 against SARS-CoV-2 Delta VOC Safety and Immunogenicity of Based Covid-19 Vaccine Candidates Ultrapotent antibodies against diverse and highly 784 transmissible SARS-CoV-2 variants Increased resistance of SARS-CoV-2 variant P.1 to antibody 787 neutralization Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. 790 Nature mRNA vaccine-elicited 793 antibodies to SARS-CoV-2 and circulating variants V2 escapes neutralization by South African COVID-19 donor plasma Structural basis of a shared antibody response to SARS-CoV-2 Recognition of the SARS-CoV-2 801 receptor binding domain by neutralizing antibodies 803 (2020c). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 804 and SARS-CoV Evidence of escape of SARS-CoV-2 variant B.1.351 from natural 806 and vaccine induced sera Evidence of escape of SARS-809 CoV-2 variant B.1.351 from natural and vaccine-induced sera Multiply attenuated 811 lentiviral vector achieves efficient gene delivery in vivo